Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Secondary Stroke Prophylaxis with Clopidogrel Produces Sufficient Antiplatelet Response

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Self-Reported Physical Activity and Cardiovascular Disease Risk Factors in Patients with Lacunar Stroke

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Computed Tomography--Verified Leukoaraiosis Is a Risk Factor for Post-thrombolytic Hemorrhage

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prediction of major vascular events after stroke: the stroke prevention by aggressive reduction in cholesterol levels trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. E-learn Computed Tomographic Angiography: A Proposed Educational Tool for Computed Tomographic Angiography in Acute Stroke

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Multiple Fractures and Impaired Bone Fracture Healing in a Patient with Pycnodysostosis and Hypophosphatasia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Bone turnover markers in children and adolescents with type 1 diabetes-A systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Role of the purinergic P2X receptors in osteoclast pathophysiology

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

BACKGROUND: Antiplatelet therapy is a cornerstone prevention strategy for secondary ischemic stroke (IS) and transient ischemic attack (TIA). Yet, a proportion of patients who receive antiplatelet therapy experience recurrent ischemic cerebrovascular events. A recent meta-analysis found an increased risk of recurrent stroke in clopidogrel- or aspirin-treated patients with ischemic stroke who had high on-treatment platelet reactivity (HTPR). Few studies have focused specifically on clopidogrel HTPR. Therefore, the aim of this study was to examine the relationship between clopidogrel HTPR and recurrent ischemic events in a population of Danish patients with IS.

METHODS: We performed a prospective observational study to evaluate the relationship between HTPR defined as platelet reaction units >208 and a composite primary endpoint of recurrent stroke, TIA, acute myocardial infarction (AMI), or vascular death over a 2-year follow-up period.

RESULTS: A total of 142 patients were included in the final statistical analysis, but only 3 patients (2.1%) demonstrated clopidogrel HTPR. The median time of on-treatment platelet testing was 75 days. Recurrent IS, TIA, AMI, or vascular death occurred in 14 patients (10%). Of these, 1 new ischemic event (AMI) occurred in a HTPR patient. There was no difference in the frequency of new ischemic events between the HTPR and non-HTPR groups (P = .27); moreover, the number of patients with HTPR was too small for statistical analysis.

CONCLUSIONS: Clopidogrel HTPR does not seem to be a major contributor to recurrent ischemic events in Danish ischemic stroke patients.

OriginalsprogEngelsk
TidsskriftJournal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
Vol/bind27
Udgave nummer10
Sider (fra-til)2683-2690
Antal sider8
ISSN1052-3057
DOI
StatusUdgivet - okt. 2018

ID: 55801356